bims-spamet Biomed News
on Spatial metabolomics of T cells
Issue of 2026–11–22
ten papers selected by
Peio Azcoaga, Katholieke Universiteit te Leuven



  1. Res Sq. 2026 Nov 05. pii: rs.3.rs-10911194. [Epub ahead of print]
      Single-cell spatial transcriptomics is now central to studying tumors in their native tissue context. Here we present the first comprehensive, independent evaluation of Atera, a new spatial whole-transcriptome platform, compared with Xenium in human ductal carcinoma in situ (DCIS). We show that Atera enables granular cell-state annotation and resolves rare cell populations, experimentally validated by multiplex immunofluorescence (IF). We further show that its transcriptome-wide coverage enables inference of copy-number alterations at single-cell resolution, allowing us to reconstruct the clonal evolution of DCIS. We orthogonally confirm the inferred copy-number alterations by whole-genome sequencing of 16 microdissected tumor regions from consecutive tissue sections. Finally, by mapping the immune microenvironment onto this clonal architecture, we demonstrate the feasibility of tracking the changes in immune response along the clonal tumor evolution in situ. Together, our results establish Atera as a validated platform for tracking clonal evolution and immune adaptation in clinical samples.
    DOI:  https://doi.org/10.21203/rs.3.rs-10911194/v1
  2. J Exp Med. 2026 Dec 07. pii: e20261316. [Epub ahead of print]223(12):
      The liver constitutes a distinct immunological niche in which CD8+ T cells balance immune protection and tissue integrity. How chronic liver disease (CLD) remodels human liver-resident CD8+ T cells remains poorly understood. We demonstrate that activated hepatic stellate cells (HSCs) create immunoinstructive fibrotic niches that regulate liver-resident CD8+ T cell differentiation, localization, and function. CD103-expressing liver-resident CD8+ T cells accumulate with increasing fibrosis severity and preferentially localize within collagen-rich scar tissue. HSC-derived and matrix-retained TGFβ promote acquisition of a residency program characterized by upregulation of CD103, ECM-binding integrins, and adhesion molecules. Despite their increased abundance, liver-resident CD8+ T cells in CLD exhibit impaired antigen-dependent effector function, increased inhibitory receptor expression, and a transcriptional program associated with T cell dysfunction. Importantly, responses to PMA/ionomycin remain intact, indicating preserved effector competence. Mechanistically, HSCs directly suppress antigen-specific liver-resident CD8+ T cell function, with partial restoration following PD-L1/PD-L2 blockade. These findings identify the fibrotic niche as a central regulator of liver-resident CD8+ T cells and reveal how fibrosis can limit local immunosurveillance.
    DOI:  https://doi.org/10.1084/jem.20261316
  3. J Immunol. 2026 Nov 02. pii: vkag315. [Epub ahead of print]215(11):
      CD8+ T cells are central mediators of adaptive immunity that eliminate infected cells and establish long-term immunological memory. Upon antigen encounter, naïve CD8+ T cells undergo rapid clonal expansion and differentiate into diverse effector and memory populations shaped by antigenic and inflammatory cues. Rather than following a single fixed pathway, this differentiation is increasingly recognized as a flexible and dynamic program that generates heterogeneous subsets with distinct functional and developmental potentials. CD8+ T-cell fate decisions are governed by the integration of multiple factors, including T-cell receptor signal strength, antigen exposure history, inflammatory cues, tissue context, host-specific factors, and antigen persistence, collectively driving the diversification of memory CD8+ T-cell populations. This review discusses current concepts in CD8+ T-cell differentiation, with a particular focus on the emergence, diversification, and functional heterogeneity of memory CD8+ T-cell subsets.
    Keywords:  CD8+ T cell; differentiation; heterogeneity; memory cells
    DOI:  https://doi.org/10.1093/jimmun/vkag315
  4. Cell Commun Signal. 2026 Aug 22. pii: 616. [Epub ahead of print]24(1):
       BACKGROUND: CD8+ T lymphocytes are critical for rejecting cancer cells but often lose functionality in the immunosuppressive tumor microenvironment. Understanding this process could improve cancer immunotherapy. The enzyme GGPS1, which produces geranylgeranyl pyrophosphate (GGPP), has an unclear impact on CD8+ T cell cytotoxic function and tumor immune escape in clear cell renal cell carcinoma (ccRCC).
    METHODS: To investigate how GGPS1 deficiency in T cells affects tumor progression, we established Renca tumor models in mice with T-cell-specific deletion of GGPS1. A combination of approaches-including real-time PCR, western blotting, flow cytometry, in vitro cytotoxicity assays, Seahorse metabolic analysis, and measurements of glucose uptake and lactic acid secretion-was employed to dissect the role of GGPS1 in CD8⁺ T cell cytotoxicity and glycolysis. In parallel, adoptive transfer studies were conducted to evaluate the antitumor potential of CD8⁺ T cells engineered to overexpress GGPS1.
    RESULTS: CD8⁺ T cells isolated from ccRCC patients who failed to respond to PD-1 blockade exhibited markedly lower GGPS1 expression. In mice, T-cell-specific deletion of GGPS1 accelerated tumor growth, accompanied by diminished infiltration of cytotoxic CD8⁺ T cells and elevated expression of exhaustion markers-including PD-1, TIM-3, LAG-3, and TOX-on tumor-infiltrating CD8⁺ T cells. Silencing GGPS1 impaired cytokine production and antitumor activity, whereas restoring GGPS1 expression reinforced both functions. Notably, exogenous GGPP fully rescued the defects in cytotoxicity and glycolysis induced by GGPS1 knockdown. Mechanistically, GGPS1 promoted MEK/ERK signaling, and the MEK inhibitor trametinib abolished GGPP-driven enhancement of CD8⁺ T cell cytotoxicity and glycolysis. Finally, elevating GGPS1 levels in CD8⁺ T cells boosted the efficacy of both adoptive immunotherapy and immune checkpoint blockade in ccRCC models.
    CONCLUSIONS: These findings highlight the essential function of GGPS1 in regulating glycolysis and cytotoxicity in CD8+ T cells, offering potential therapeutic strategies for clinical tumor immunotherapy in ccRCC.
    Keywords:  GGPS1; Glycolysis; Immunotherapy; T cell
    DOI:  https://doi.org/10.1186/s12964-026-03167-6
  5. Cell Commun Signal. 2026 Aug 26. pii: 625. [Epub ahead of print]24(1):
       BACKGROUND: Anti-programmed cell death protein 1 (anti-PD-1) therapy is a standard treatment for advanced lung cancer, but its efficacy is often limited by resistance, driven largely by an immunosuppressive tumor microenvironment. Methyltransferase-like 3 (METTL3), a core N6-methyladenosine (m6A) writer, plays a key role in immune regulation and has emerged as a critical modulator of the immunosuppressive tumor niche. Beyond its canonical m6A-catalytic function, METTL3 also exhibits non-catalytic activities and is itself regulated by acetylation. However, its non-catalytic and acetylation-dependent roles in anti-PD-1 resistance remain to be elucidated.
    METHODS: METTL3 expression in anti-PD-1-resistant lung cancer cells was assessed by immunohistochemistry and Western blotting. Its in vivo function was evaluated using subcutaneous and orthotopic tumor models under anti-PD-1 treatment. CD8+ T cell exhaustion was examined by single-cell RNA sequencing and flow cytometry. Mechanistic studies included genetic manipulation, polysome profiling, co-immunoprecipitation, and RNA immunoprecipitation. Clinical relevance was validated in human lung cancer samples via immunohistochemistry and multiplex immunofluorescence. Statistical analyses involved unpaired two-tailed Student's t-test, one-way/two-way ANOVA, and Pearson's correlation.
    RESULTS: METTL3 was upregulated in anti-PD-1-resistant lung cancer cells and it promoted anti-PD-1 resistance in both subcutaneous and orthotopic mouse models. Mechanistically, METTL3 induced CD8+ T cell exhaustion via upregulation of secreted phosphoprotein 1 (SPP1). This occurred independently of its m6A catalytic activity, potentially through direct interaction with eukaryotic translation initiation factor 3 subunit H (EIF3H) to facilitate SPP1 translation. Furthermore, METTL3 protein stability was enhanced by lysine acetyltransferase 5 (KAT5)-mediated acetylation, which attenuated ubiquitin-dependent degradation. Finally, critical nodes of the KAT5-METTL3-SPP1 axis were validated in human lung cancer cells, and METTL3 expression positively correlated with KAT5, SPP1, and CD8+ T cell exhaustion markers in clinical samples.
    CONCLUSION: We identified a novel KAT5-METTL3-SPP1 axis that drives anti-PD-1 resistance by inducing CD8+ T cell exhaustion. Notably, METTL3 functions through a non-m6A catalytic mechanism involving translation and acetylation. These findings provide new mechanistic insights and potential therapeutic targets for overcoming anti-PD-1 resistance in lung cancer.
    Keywords:  Acetylation; Anti-PD-1 resistance; CD8+ T exhaustion; KAT5; SPP1; Stabilization of METTL3
    DOI:  https://doi.org/10.1186/s12964-026-03176-5
  6. Cancer Immunol Immunother. 2026 Aug 22. pii: 284. [Epub ahead of print]75(12):
      The development of immune checkpoint inhibitors has improved the treatment outcomes for patients with many types of cancer. However, the clinical benefits remain limited in many patients, highlighting the need for novel therapeutic strategies to enhance antitumor immunity. Hepatocyte nuclear factor 1A (HNF1A) is a transcription factor that regulates the expression of several liver-specific genes, and its expression is increased in certain cancers, such as colon and non-small cell lung cancer (NSCLC), compared with normal tissue. However, the effects of HNF1A on antitumor immunity remain unknown. Here, we show that colon cancer and NSCLC expressing HNF1A activate antitumor immunity. HNF1A-overexpressing cancer cells activated T-cell-mediated anticancer cytotoxicity when co-cultured with peripheral blood mononuclear cell-derived T cells. In a syngeneic mouse model, MC38 colon adenocarcinoma growth was suppressed after subcutaneous injection of HNF1A-overexpressing cancer cells. Flow cytometry analysis of tumor-infiltrating T cells showed that CD8+ T cells increased and were functionally activated in tumors overexpressing HNF1A. Treatment with an anti-PD-1 monoclonal antibody reduced tumor growth in HNF1A-overexpressing tumors. These results suggest that HNF1A plays a role in antitumor immunity and may influence the response to immune checkpoint blockade.
    Keywords:  Antitumor immunity; Colon cancer; Hepatocyte nuclear factor 1A (HNF1A); Non-small cell lung cancer; Programmed cell death 1 (PD-1); Tumor-infiltrating lymphocytes
    DOI:  https://doi.org/10.1007/s00262-026-04533-6
  7. Biochem Pharmacol. 2026 Nov 19. pii: S0006-2952(26)01022-1. [Epub ahead of print] 118679
      Breast cancer exhibits profound spatial heterogeneity in immune evasion, with conventional bulk omics unable to resolve intratumoral immunosuppressive gradients that drive variable drug response and therapeutic resistance. Existing reviews largely focus on spatial omics technologies or tumor immunology and lack a pharmacological framework for understanding how spatial architecture shapes drug-target accessibility, intratumoral drug exposure, and zone-specific resistance. Building on the emerging concept of spatial pharmacology, this review extends its application by integrating tumor spatial microenvironment structure, spatial cell-cell interactions, spatial multiomics mapping, and regional drug distribution to address spatial heterogeneity-mediated drug sensitivity and resistance. We describe subtype-specific spatial immune evasion features, spatial omics technologies, and spatial pharmacology in breast cancer - including spatial profiling of drug distribution, omics-driven target discovery, druggability evaluation, and the corresponding resistance mechanisms and therapeutic strategies. Current limitations include technical bottlenecks in spatial resolution, insufficient druggability validation of spatial targets, and translational gaps between spatial discovery and clinical drug development. In the future, spatial pharmacology will provide guidance for the stratification of precision immunotherapy and accelerate the development of spatially informed drug therapies for breast cancer.
    Keywords:  Breast cancer; Immunotherapy resistance; Spatial pharmacology; Spatial transcriptomics; Tumor immune microenvironment
    DOI:  https://doi.org/10.1016/j.bcp.2026.118679
  8. PLoS One. 2026 ;21(11): e0362939
      Resistance to immune checkpoint inhibitors (ICIs), including anti-PD-L1 therapies, remains a major challenge in cancer treatment, with many patients relapsing despite initial responses. Here, we develop a mathematical model to investigate a mechanism of anti-PD-L1 resistance driven by age-associated senescence of CD8+ T cells, in which senescent T cells (Ts) secrete VEGF, thereby promoting tumor growth through enhanced vascular support. To counteract this effect, we incorporate the senolytic drug navitoclax (ABT-263), which selectively eliminates senescent T cells, and evaluate the efficacy of combined senolytic-anti-PD-L1 therapy in extending tumor remission. Model predictions are validated against independent murine data involving navitoclax and anti-PD-L1 treatment. The model is used to study different strategies of combining the senolytic drug with anti-PD-L1, in order to maximize the remission time of the combined treatment. The optimal starting time of the treatment with the senolytic drug depends on the senescent-to-functional T cells ratio, Ts/T. The paper identifies immune senescence as an important determinant of response to cancer immunotherapy.
    DOI:  https://doi.org/10.1371/journal.pone.0362939
  9. J Transl Med. 2026 Aug 24. pii: 1440. [Epub ahead of print]24(1):
      Tumor-associated macrophages (TAMs) play a pivotal role in tumor progression and immune evasion, with recent evidence indicating that metabolic reprogramming is crucial in determining their functional phenotype. Alterations in glucose, amino acid, and lipid metabolism are central to the regulation of TAMs plasticity, driving the shift between pro-inflammatory (M1) and anti-inflammatory (M2) states. M1 macrophages predominantly rely on glycolysis and aerobic metabolism to support their pro-inflammatory functions, while M2 macrophages exhibit enhanced oxidative phosphorylation, which facilitates tissue repair and immune suppression. Given these metabolic distinctions, targeting key metabolic pathways in TAMs presents a promising strategy for reprogramming the tumor microenvironment and enhancing anti-tumor immunity. This review examines the metabolic differences between these distinct macrophage populations, focusing on the regulation of glucose, amino acid, and lipid pathways. Furthermore, we evaluate emerging therapeutic strategies targeting these metabolic pathways aimed at reprogramming TAMs toward an anti-tumor phenotype, enhancing anti-tumor immunity, and overcoming therapeutic resistance. Finally, we discuss the translational progresses and challenges of metabolic interventions, highlighting the potential of targeting macrophage metabolism to convert refractory tumors into immunologically responsive ones and improve the clinical outcomes of cancer immunotherapy.
    DOI:  https://doi.org/10.1186/s12967-026-08845-0
  10. Sci Immunol. 2026 Nov 20. 11(125): eaej5412
      Aging profoundly alters CD8 T cells, driving senescence and exhaustion that contribute to immune decline. By mapping chromatin accessibility across functional and dysfunctional CD8 T cell subsets from young and aged mice, we found that age-related CD8 T cell dysfunction was associated with a loss of regulation at three distinct levels. Dysfunctional CD8 T cells showed reduced accessibility of genes essential for "stemness," indicating diminished regenerative potential. Exhausted memory T cells (Tmem cells) showed decreased accessibility of "restraint" genes, which limit differentiation postactivation. Last, both senescent virtual memory T cells (TVM cells) and exhausted Tmem cells displayed increased accessibility of "terminal inhibitory" genes, underscoring progression toward irreversible dysfunction. The inhibitory receptor gene Fcgr2b, encoding FcγRIIb/CD32b, was notably increased in a subset of aged TVM cells with regulatory characteristics. This study defines mechanisms of CD8 T cell aging and identifies a CD8 regulatory T cell (Treg cell) population that emerges as a hallmark of aging.
    DOI:  https://doi.org/10.1126/sciimmunol.aej5412